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Summary 
Neither chemotherapy nor radiotherapy alone is adequate to treat both bulky local 
disease and the almost universal distant micrometastases of small cell lung cancer (SCLC). 
Despite improved overall and 2-year survival rates associated with combining the two 
treatment modalities, however, their potential for toxic interaction demands careful con- 
sideration. The specific toxicity profile of the chemotherapeutic agent used must be 
calculated and balanced with the radiotherapy dose, fractionation, volume, and timing 
with chemotherapy to give the patient the maximum benefit and the least amount of risk. 
Results of clinical trials indicate that fractionation of the radiation dose takes advantage 
of the fact that fractionation causes less damage to and allows for repair of normal tissue, 
whereas the tumor cells of SCLC are killed exponentially by even small radiation doses 
per fraction. Further evaluation of radiation volume is needed to answer questions on the 
risk-benefit ratio of normal lung exposure versus complete coverage of areas of potential 
metastasis, and to determine whether dose of volume is the more critical factor for lung 
toxicity. Finally, the timing of radiotherapy also must be studied further. Early 
radiotherapy offers the potential for killing small cells before they migrate, but attempts 
to compensate for such early exposure may lead to subtherapeutic doses of chemotherapy 
and, thus, to lower response rates. 
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Introduction 
Since the 1960s progress in the treatment of small cell lung cancer (SCLC) has been 
encouraging. Admittedly, some of this progress may be the result of improved staging 
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techniques and the inclusion of only those patients with limited-stage disease in clinical 
trials, but significant changes in our approach to the management of SCLC have also af- 
fected outcome favorably. 
In the 1960s it became apparent that surgery alone did not completely resect SCLC, as 
disease in these patients rapidly progressed with distant metastases. Radiotherapy provid- 
ed better local control and survival for most patients, but also proved incapable of aver- 
ting disease dissemination. Subsequently, chemotherapy became the cornerstone of 
therapy for SCLC, whether limited or extensive. 
The need for chemotherapy is unquestioned, since the great majority of patients with 
SCLC have a form of extensive disease. Even when SCLC is categorized as limited to the 
chest, only rarely are distant micrometastases absent. Nevertheless, in limited disease the 
metastases are clinically occult-beneath the level of detection of current imaging 
modalities, which require at least lo8 cells to be visualized. 
Despite improved response rates with chemotherapy during the 1970s and early 198Os, 
survival rates were only marginally affected; median survival rarely exceeded 12-14 
months. By itself, then, chemotherapy was unable to manage bulky disease of the chest 
adequately, and, ultimately, intrathoracic recurrence was seen in 80- 100% of patients so 
treated. For this reason, radiotherapy was reintroduced to the therapeutic regimen. How- 
ever, early attempts to use chemoradiotherapy were marred by excess to toxicity. 
Combination Chemotherapy/Radiotherapy 
A 1983 review of the literature by the International Association for the Study of Lung 
Cancer [l] noted that chemotherapy in combined-modality trials was generally based on 
cyclophosphamide, most commonly combined with doxorubicin and vincristine. These tri- 
als, which added continuous or split-course radiotherapy to cyclophosphamide-based 
chemotherapy showed improved survival in only two of the seven trials. The methods of 
combining chemotherapy with radiotherapy, the cyclophosphamide-based chemotherapy, 
split-course, low-dose, early technology may explain these results. However, because of 
the diagnostic imaging revolution, it is difficult and imprecise to compare studies from 
more than a decade ago with results today. 
Dangerous liaisons: toxicities of combination therapy 
Combining thoracic irradiation with doxorubicin (a cardiotoxin), bleomycin, mitomy- 
tin, or the nitrosoureas (lung toxins), greatly increases the risk of cardiac, esophageal, and 
lung toxicity associated with radiotherapy alone. Usual subliminal or rare toxicities may 
be promoted to more commonplace events. The expected timing of toxicities may also be 
altered. Radiation pneumonitis usually occurs at 2-6 months. When bleomycin, 
lomustine, or mitomycin is used, pneumonitis can be seen much earlier, even during 
radiotherapy. Obviously, the damage is caused by the therapy, but its manifestation is 
delayed until months later. Using both modalities eliminates this latency period. This sug- 
gests that the chemotherapeutics may lower the threshold for radiation pneumonitis, 
perhaps in these instances better called combined-modality pneumonitis. 
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Considerations for planning radiotherapy 
Radiation technology has evolved significantly over the past 90 years. Magnetic reso- 
nance and computed tomography (CT) imaging techniques, for example, have improved 
to allow more specific disease localization and radiation targeting, while simulators and 
CT scanners provide more accurate planning of radiotherapy. Radiotherapy planning in- 
volves steps to design radiotherapy field sizes as well as sizes, shapings, angles, and depths 
of the fields. These procedures allow a tumor coverage to be optimized, while limiting the 
exposure of normal tissues. Dose, fractionation, volume, and timing with chemotherapy 
are the four important considerations concerning the influences of radiotherapy in lung 
cancer. 
Dose and fractionation 
The total radiation dose and fractionation - or the daily dose and total time to achieve 
that dose - influence not only the actual physical dose but also its effective biologic im- 
pact. Altered fractionation and combination with chemotherapy change acute effects to 
tumor and normal tissues and late effects, such as local control of tumor and normal tissue 
fibrosis in lung, strictures to the oesophagus, and genetic damage leading to second tu- 
mors. Commonly, in former methods, chemotherapy was administered first, followed by 
radiotherapy (the sequential method). Retrospective analysis of the effect of dose on 
locoregional failure rates shows that, at lower doses, disease recurs in SO-90% of patients 
within a 3-year period (Fig. 1). Even at doses of 40, 45 and 50 Gy, 30-50% of patients 
will experience local recurrence [2]. Clearly, these doses administered sequentially are in- 
adequate for local control; when chemotherapy alone is used, local failure occurs in 
SO-100% of patients [3]. 
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Fig. 1. Effect of radiation dose on horegional failure rate. 
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about radiation response in normal tissues and tumors. Most normal tissues and tumors 
have an initial region where dose appears to accumulate before exponential cell killing is 
observed. This region is called the radiobiologic shoulder. Classic SCLC cells have no 
shoulder; lymphocytes are a normal cell population with this characteristic. Thus, smaller 
fractions of radiation kill SCLC exponentially at doses that merely damage many normal 
tissues [4]. Exploiting this difference provides a potentially therapeutic advantage. Small 
fractions cause less damage to tissues with a radiobiologic shoulder, like normal lung and 
spinal cord tissue. At the same time, the interval between fractions allows both repair of 
sublethal damage to normal tissue and passage of the surviving SCLC cells from the 
relatively resistant S-phase of the cell cycle to the more sensitive GZ- or M-phase. In view 
of the very short doubling time and rapid growth of SCLC, cycle redistribution may be 
important. Unfortunately, the non-SCLC histologies and the variant SCLCs have 
radiobiologic shoulders, so there may be less reason for hyperfractionation schemes. 
Nevertheless, the prospect of repopulation of tumor during protracted fractionation 
schedules continues to make accelerated schemes an appealing strategy. Thus, there is a 
special reason to attempt altered fraction schemes in limited SCLC. 
Volume 
The radiation field must balance the necessary exposure of.tumor cells with the need 
to protect normal tissue. Entering and exiting beams expose normal tissues. Standard 
techniques include a margin of normal tissue to allow for a variation in setup, tumor mo- 
tion, uncertainties of tumor extent, and physical buildup of dose. Older radiotherapy 
techniques applied to protect the spinal cord commonly block radiation to the 
mediastinum, which, prior to CT scans, was a poorly visualized area that commonly har- 
bored bulky subcarinal nodes. At the same time, clinically uninvolved contiguous areas 
of lymphatics have been irradiated. This expands the volume of normal tissue irradiated. 
As the Halsted or ‘en bloc’ approach was initially applied to breast cancer, these expanded 
volumes have been attempted in lung cancers. Similarly, the success of expanded fields in 
the treatment of Hodgkin’s disease unfortunately has not been mirrored when these 
strategies have been applied to lung cancer. Since contiguous spread to lymphatics seems 
isolated to Hodgkin’s disease and the ‘en bloc’ approach has faltered elsewhere, it should 
not be surprising that treatment of neighboring nodal regions does not improve outcome 
in lung cancer. Supraclavicular nodes are infrequent sites of exclusive failure, and failure 
at these sites has been associated with distant rather than local failure [5]. Clearly, expan- 
sive radiotherapy fields expose larger areas of normal tissue to toxicity and, while such 
a compromise might be acceptable were radiotherapy used alone, volume merits careful 
reconsideration when combined modalities are used. 
When the target volume is limited to the tumor, first echelon nodes, and less generous 
margins of normal tissues, methods can be designed to treat this target and expose the spi- 
nal cord and lung to lower, more tolerable doses. Many propose that the prechemotherapy 
tumor volume dictates the target. This clearly is the case for concurrent chemoradio- 
therapy during Cycle 1 treatment since there is no reduced volume. However, one advan- 
tage of delaying thoracic therapy to later cycles is the potential to trim the volume. 
Whether this reduces local control or compromises survival has not been subjected to trial. 
When patients achieving a complete response were randomized to radiotherapy versus ob- 
servation, a Southwest Oncology Group (SWOG) trial could demonstrate no benefit to 
the radiotherapy [6] but analyzing volume in this study suggested that the volume ir- 
radiated had little influence on either survival or local control. 
Two trials have looked at the timing-early versus delayed-of thoracic radiotherapy. In 
one such study, delaying thoracic radiotherapy to Cycle 4 allowed full doses of chemother- 
apy to be given and, compared with chemotherapy alone or with immediate radiotherapy 
at Cycle 1, produced the best survival [7]. Murray and colleagues [8] in a National Cancer 
Institute of Canada trial randomized patients to platinumetoposide with concurrent 
radiotherapy at either Cycle 2 or Cycle 6 and observed a survival benefit for early 
radiotherapy. 
Clinical Application of RadiothepapyKhemotherapy 
Three methods of integrating thoracic radiotherapy and chemotherapy have been used 
in limited SCLC trials: sequential, alternating, and concurrent. The sequential strategy ap- 
pears to have inferior results. This may be due to types of chemotherapy used or subop- 
timal doses, volumes, or fractionation schemes. Studies comparing alternating or 
concurrent methods to sequential methods need to use programs providing equal toxicity- 
which may be difficult to estimate. 
The alternating approach to integrating chemotherapy and radiotherapy uses both 
treatments at full dose whenever possible, with radiation administered in split courses. 
Usually, the therapies are alternated rapidly, with one modality used one week and the 
other used the following week. In the third week, treatment returns to that of week 1 or 
is delayed to allow recovery from the toxic effect of the first 2 weeks. 
Numerous clinical trials have incorporated technically different radiotherapeutic ap- 
proaches with chemotherapy. A reanalysis of the 1970 National Cancer Institute (NCI) 
data suggested that 3 weeks of concurrent chemoradiotherapy was optimal [9]. 
Coupled with the biologic information that SCLC lacks a shoulder, these data formed 
the underpinning of a trial initiated at the University of Pennsylvania in 1984 [5]. 
The induction schema of the Penn Study is shown in Fig. 2. Cisplatin 60 mg/m2 was 
given on day 1 and etoposide 120 mg/m* on days 4, 6 and 8. Thoracic radiotherapy was 
administered twice daily and concurrently in this study, beginning on day 1. On day 22, 
patients were given full Cycle 2 doses of cisplatin/etoposide, irrespective of nadir blood 
counts or severity of esophagitis. All radiotherapy was completed by day 21, delivering 
a tumor dose of 45 Gy in 3 weeks. 
Of 32 patients in this trial, 73% developed Grade 3 or 4 myelotoxicity. In fact, data from 
subsequent Eastern Cooperative Oncology Group (ECOG) and other groups support that 
Grade 3 or 4 leukopenia appears to develop in 60-75% of patients treated with compar- 
able regimens [lo-121. Acute esophageal toxicity (Grade 2, mild difficulty in swallowing, 
or Grade 3, able to swallow liquids but not solids) were each noted in approximately 40% 
of patients in the original Penn and the subsequent ECOG confirmatory trial, which was 
a multi-institutional pilot study of the same treatment program. In contrast to earlier trials 
that used cyclophosphamide-based chemotherapy, however, esophageal toxicity was 
reversible in these patients; no strictures were produced in long-term survivors [lo]. 
Survival data for the concurrent cisplatin/etoposide/twice-daily thoracic radiotherapy 
studies show that disease-free survival remains at approximately 50%, but the different in- 
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Fig. 2. Induction schema for trial of cisplatin/etoposide and thoracic radiotherapy. Radiation fields are shown. 
Reprinted from Turrisi et al. (see Ref. 5) with permission. 
stitutions have discordant disease relapse patterns beyond 2 years. At a minimum follow- 
up of 48 months, 5-year disease-free survival is still flat at 40-50% in the Penn study [17] 
(Fig. 3). 
Comparing these figures globally with studies by SWOG [13], NC1 [ 141 and ECOG 
[ 10,151, the median survival times for patients with SCLC treated with a total radiation 
dose of 45 Gy (Table I), given once or twice daily, approach 2 years, with actuarial 2-year 
survivals of 40 to 60%. 
The current ECOG trial 3588 used only four cycles of cisplatin 60 mg/m2 on day 1 and 
etoposide 120 mg/m2 on days 1, 2 and 3. In contrast, the earlier Penn [5] and ECOG 
[ 10,151 trials used five cycles of these drugs alternated with CAV (cyclophosphamide/dox- 
orubicinlvincristine) as maintenance therapy. Prophylactic cranial irradiation (PCI) was 
provided to complete responders, but was administered at the end of therapy. In ECOG 
trial 3588, cisplatin/etoposide was given concurrently with thoracic radiotherapy, but pa- 
tients were randomized to 45 Gy either twice daily for 3 weeks or once daily for 5 weeks 
(Table 2). Very few differences are worthy of note concerning acute and late effects. 
Responses were the best seen in any ECOG trial, and myelosuppression, esophageal toxic- 
ity, and the incidence of toxic deaths were similar in the two groups. 
The effect of hypofractionation was evaluated in a recent study by Prendiville et al. [16], 
who compared thoracic radiotherapy administered as a single 12.5-Gy dose, with 10 frac- 
Sl15 



















Median = 17 mo 
0 I I I I I I 1 
0 20 40 60 60 
Months 
Fig. 3. Progression-free survival in patients receiving twice-daily radiation concurrent with cisplatinktoposide. 
tions of 2.75 Gy, for a 27.5-Gy total dose. Acute toxicity was essentially similar between 
the two groups, but late toxicity in the group receiving the single dose was almost twice 
that associated with the hyperfractionation regimen. Acute toxicity for these infrequent 
fractionation groups was similar to that reported in twice-daily radiotherapy trials, but 
these late effects were not seen. In most trials using a total dose of 45 Gy (given once or 
twice daily) concurrent with cisplatin/etoposide chemotherapy, the local failure rate is 
reported to be below 10%. So, isoeffect acute end points with different radiotherapy 
schedules did not produce similar late effects. Hypofractionated schedules produce poorer 
local control and excess late effects when compared with standard, accelerated, or hyper- 
fractionated schedules. In the Prendiville trial [ 161, PC1 was optional; approximately 26% 
of patients had metastases to the brain, similar to the 20% actuarial rate associated with 
use of PC1 and substantially less than the 40% incidence when PC1 is omitted. 
TABLE 1 
Chemotherapy with concurrent thoracic radiotherapy: results of trials in patients with limited SCLC. 
Reference No. patients Chemotherapy Radiation Survival 
dose (Gy) 
Median (months) 2-Year (%) 
SWOG [13] 154 PEV 45 daily 18 45 
Penn (51 32 PE 45 b.i.d. 23 45 
NC1 (141 23 PE 45 b.i.d. 24 60 
ECOG I [IO] 37 PE 45 b.i.d. 22 40 
ECOG II (151 34 FE 45 24 40 
ah-b.i.d. 
PEV, cisplatinletoposideiincristine; ah, alternating with. 
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TABLE 2 
Relative scales: once- vs. twice-daily dosing (total dose, 45 Gy) 
Method No. fractions Dose 
(GY) 
No. treatment RET 
days 
Gy-10 N-RET Gy-3 
Once daily 25 1.8 33 1415 53 666 72 
Twice daily 30 1.5 19 1438 52 844 68 
RET, radiation equivalent therapy, a measure of acute effects; NRET, neurolytic RET, a measure of late effects. 
Conclusions 
Some therapeutic gains have been offset by excess toxicity. This paper has reviewed the 
conceptual basis for adding thoracic radiotherapy to systemic chemotherapy to treat limit- 
ed SCLC. The choice of chemotherapy clearly influences the tolerance. In the 199Os, cis- 
platin/etoposide regimens can be integrated with radiotherapy with less toxicity and 
apparently more efficacy. 
Methods of administering the thoracic radiotherapy may also influence outcomes. 
Large volumes and large fraction sizes lead to large frequencies of untoward effects. 
Trimmed volumes compromise inclusion of lymph nodes but allow for more intense irradi- 
ation to areas of bulk that may harbor resistant cells inaccessible or unresponsive to 
chemotherapy. 
PC1 provides an opportunity to eliminate those cells that have a relative sanctuary from 
chemotherapy. It has been used for 20 years, but has a frequency of late effects and fails 
to influence survival. Nevertheless, it clearly reduces the devastating effects of brain 
metastasis. Because of this controversy, further studies are needed to settle the debate. 
In summary, targeted fractionated thoracic radiotherapy integrated in the Iirst weeks 
or months of SCLC chemotherapy with cisplatin/etoposide regimens is associated with 
better survival and local control than have been seen in historical controls. The use of PC1 
is contentious, and no clear survival advantages are afforded. 
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